Abbott India Ltd.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest day gain of 0.71%, the stock’s broader technical landscape suggests caution for investors as bearish signals intensify across multiple timeframes.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift markedly, moving from expensive to very expensive territory. Despite a modest day gain of 0.71%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now stand well above peer averages, raising questions about price attractiveness amid mixed returns compared to the broader market.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and has implications for investors assessing the stock’s price attractiveness relative to its historical and peer benchmarks.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters reveal a landscape of cautious optimism tempered by underlying weaknesses.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 12 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The stock’s recent performance, combined with mixed technical signals, suggests increased caution for investors amid a challenging market backdrop.

Abbott India Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 12 May 2026. This shift reflects a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite strong long-term returns and robust management efficiency, the company faces challenges from stretched valuations and a mixed technical outlook, prompting a more cautious stance from analysts.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its quality grade downgraded from ‘Excellent’ to ‘Good’ by MarketsMOJO, accompanied by a shift in its Mojo Grade from Hold to Sell as of 12 May 2026. This change reflects a nuanced alteration in the company’s business fundamentals, with certain key metrics showing improvement while others indicate a deterioration in operational consistency and financial quality.

Abbott India Ltd., one of the leading multinational pharmaceutical companies in India with operations spanning owned manufacturing facilities and third-party contractors, reported net profit of ₹394.93 crores for Q4 FY26 (quarter ending March 2026), representing a sequential increase of 5.05% from Q3 FY26's ₹375.96 crores and a year-on-year growth of 7.60% from ₹367.04 crores in Q4 FY25. With a market capitalisation of ₹57,361.75 crores, the stock traded at ₹26,994.65 on May 12, 2026, down 2.82% on the day, reflecting investor caution despite the company's resilient operating performance.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 6 May 2026. This shift reflects nuanced changes across four critical parameters: quality, valuation, financial trend, and technicals. Despite a challenging recent performance, the company’s strong fundamentals and evolving market signals have prompted a reassessment of its outlook.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. This change accompanies a 3.84% gain in the stock price on 7 May 2026, reflecting renewed investor interest despite mixed signals from key technical indicators.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. This change reflects evolving market perceptions and raises questions about the stock’s price attractiveness relative to its historical averages and peer group benchmarks.